Relenza Powder
NDC Package 0173-0681-22

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Relenza (zanamivir) powders is zanamivir is used to treat symptoms caused by the flu virus (influenza) if you have had symptoms for 2 days or less. This formulation utilizes a powder delivery system. Marketed by Glaxosmithkline Llc, this product is identified by NDC 0173-0681 and is authorized under FDA application NDA021036.

Identification & Billing

NDC Package Code
0173-0681-22
Package Description
5 PACKAGE in 1 CARTON / 4 POWDER in 1 PACKAGE
Product Code
0173-0681
11-Digit Billing Format
00173068122
RxNorm Crosswalk
  • RxCUI: 759471 - zanamivir 5 MG/INHAL Dry Powder Inhaler, 20 Blisters
  • RxCUI: 759471 - 20 ACTUAT zanamivir 5 MG/ACTUAT Dry Powder Inhaler
  • RxCUI: 759471 - zanamivir 5 MG/ACTUAT Dry Powder Inhaler, 20 ACTUAT
  • RxCUI: 759473 - RELENZA DISKHALER 5 MG/INHAL Dry Powder Inhaler, 20 Blisters
  • RxCUI: 759473 - 20 ACTUAT zanamivir 5 MG/ACTUAT Dry Powder Inhaler [Relenza]

Clinical Specifications

Proprietary Name
Relenza
Non-Proprietary Name
Zanamivir
Substance Name
Zanamivir
Dosage Form
Powder - An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use.
Administration Route
Respiratory (inhalation) - Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect.
Active Ingredient(s)
ZANAMIVIR 5 mg/1
Pharmacologic Class
Usage Information
Zanamivir is used to treat symptoms caused by the flu virus (influenza) if you have had symptoms for 2 days or less. It helps lessen symptoms (such as stuffy nose, cough, sore throat, fever/chills, headache, body aches, tiredness) and shortens the recovery time by about 1 to 2 days. Zanamivir may also be used to prevent the flu if you have been exposed to someone who already has the flu (such as a sick household member) or if there is a flu outbreak in the community. Talk to your doctor for more details. This medication works by stopping the flu virus from growing. It is not a substitute for the flu vaccine. If you have the flu, zanamivir does not reduce the risk of giving the flu to others.

Regulatory & Marketing

Labeler Name
Glaxosmithkline Llc
Product Type
Human Prescription Drug
FDA Application #
NDA021036
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
09-22-1999
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0173-0681). Click a package code to view its specific billing and regulatory data.

0173-0681-01
5 PACKAGE in 1 CARTON / 4 POWDER in 1 PACKAGE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0173-0681-22 identifies a specific commercial package of 5 package in 1 carton / 4 powder in 1 package of Relenza, a human prescription drug labeled by Glaxosmithkline Llc. This powder is formulated for respiratory (inhalation) use and contains zanamivir as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glaxosmithkline Llc on September 22, 1999. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Zanamivir is used to treat symptoms caused by the flu virus (influenza) if you have had symptoms for 2 days or less. It helps lessen symptoms (such as stuffy nose, cough, sore throat, fever/chills, headache, body aches, tiredness) and shortens the recovery time by about 1 to 2 days. Zanamivir may also be used to prevent the flu if you have been exposed to someone who already has the flu (such as a sick household member) or if there is a flu outbreak in the community. Talk to your doctor for more details. This medication works by stopping the flu virus from growing. It is not a substitute for the flu vaccine. If you have the flu, zanamivir does not reduce the risk of giving the flu to others.

How is this Glaxosmithkline Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00173068122. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0173-0681-22
11-Digit CMS (5-4-2)
00173-0681-22

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.